Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

NCT06283550 is registered in ClinicalTrials.gov with Innovaderm Research Inc. as lead sponsor.

NCT NCT06283550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06283550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Lead sponsor
Innovaderm Research Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2024
Completion date
November 3, 2025
Enrollment
82 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hand eczema